Ads
related to: early symptoms macular degeneration treatments- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Download The Amsler Grid
Use This Test To Help Monitor
Your Vision Between Appointments
- Resource Library
Useful Digital Resources & Tools
To Support Your Treatment Journey
- Sign Up For More Info
Sign Up Today To Receive More
Resources And Information
- Wet AMD FAQs
Search results
Results From The WOW.Com Content Network
Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. [1] Early on there are often no symptoms. [1] Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. [1]
Treatment is based on the cause of the retinopathy and may include laser therapy to the retina. Laser photocoagulation therapy has been the standard treatment for many types of retinopathy. Evidence shows that laser therapy is generally safe and improves visual symptoms in sickle cell and diabetic retinopathy.
Fundus of geographic atrophy. Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of central vision over time.
The fundus exam via ophthalmoscopy is essentially normal early on in cone dystrophy, and definite macular changes usually occur well after visual loss. Fluorescein angiography (FA) is a useful adjunct in the workup of someone suspected to have cone dystrophy, as it may detect early changes in the retina that are too subtle to be seen by ...
Laser treatment of drusen has been studied. While it is possible to eliminate drusen with this treatment strategy, it has been shown that this fails to reduce the risk of developing the choroidal neovascularisation which causes the blindness associated with age-related macular degeneration. [15]
Hence, if not treated, macular degeneration may lead to blindness. Awareness to early changes in vision, especially in high risk patients, leads to early treatment (such as intravitreal injection of anti-VEGF factors, e.g. bevacizumab or ranibizumab) and prevents loss of vision. [1]
Ads
related to: early symptoms macular degeneration treatments